Tyra Biosciences Independent Director Gilla Kaplan Sells 58% Of Holding

Some Tyra Biosciences, Inc. (NASDAQ:TYRA) shareholders may be a little concerned to see that the Independent Director, Gilla Kaplan, recently sold a substantial US$535k worth of stock at a price of US$10.32 per share. That diminished their holding by a very significant 58%, which arguably implies a strong desire to reallocate capital.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At Tyra Biosciences

Notably, that recent sale by Gilla Kaplan is the biggest insider sale of Tyra Biosciences shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$9.50. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

I will like Tyra Biosciences better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Tyra Biosciences insiders own about US$21m worth of shares. That equates to 4.1% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Tyra Biosciences Tell Us?

An insider hasn't bought Tyra Biosciences stock in the last three months, but there was some selling. And our longer term analysis of insider transactions didn't bring confidence, either. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Tyra Biosciences. To help with this, we've discovered 3 warning signs (1 is potentially serious!) that you ought to be aware of before buying any shares in Tyra Biosciences.

But note: Tyra Biosciences may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Weekly Picks from Community

Investing narratives with Fair Values

• Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges
  By Robbo – Community Contributor

  Fair Value Estimated:
  A$2.42 · 0.1% Overvalued

• Vossloh rides a €500 billion wave to boost growth and earnings in the next decade
  By Chris1 – Community Contributor

  Fair Value Estimated:
  €78.41 · 0.1% Overvalued

• Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth
  By Unike – Community Contributor

  Fair Value Estimated:
  $325.55 · 0.6% Undervalued

View more featured narratives

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.